Recurrent Lymphoepithelioma of the Nasopharynx Completed Phase 1 Trials for Everolimus (DB01590)

IndicationStatusPhase
DBCOND0029500 (Recurrent Lymphoepithelioma of the Nasopharynx)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01637194Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck CancerTreatment